程序性细胞死亡受体1与细胞毒性T淋巴细胞相关抗原4联合阻断治疗胰腺癌的研究进展
打开文本图片集
关键词：胰腺肿瘤；免疫检查点抑制剂；程序性细胞死亡受体1；CTLA-4抗原基金项目：国家自然科学基金（82360510）；陇原青年创新创业人才（团队）项目（212088725013）；兰州大学第二医院萃英科技创新计划项目（CY2022-MS-A11）
Research advances incombinedblockade therapy forprogrammedcelldeath-1andcytotoxicT-lymphocyte associatedantigen4inpancreaticcancer
QINWenke1，WEIKongyuan²，ZHAOXuean’，ZHOUWence³，ZHANGHui³
1.The SecondClinical MedicalScholofLanzhou University，Lanzhou730oo，China；2.DepartmentofHepatobiliarySurgery， TheFirstAffiliatedHospital of Xi ’an Jiaotong University，Xi' an 71Oooo，China;3.Department of General Surgery，The Second HospitalofLanzhouUniversity，Lanzhou73oooo，China
Corresponding author：ZHANG Hui，ery_huizhang@lzu.edu.cn（ORCID：0009-0005-5854-1170）
Abstract：Pancreaticcancerisahighlymalignanttumorofthedigestivesystem withanextremelyporprognosis，andtraditional treatmentmethodshavealimitedefectinprolongingthesurvivaltimeofpatients.Inrecentyears，ground-breakingadvances have beenachievedforimmunechckpoint inhibitors（ICI）inavarietyofsolidtumors，among which programmedcelldeath-1（PD-1） andcytotoxic T-lymphocyte-assciatedantigen4（CTLA-4）haveatracted muchattentionasmajor immunecheckpointtargets. Althoughsingle-agenttreatmentwithPD-1orCTLA-4inhbitorhasanunsatisfactoryefectinPC，thestrategyofdualblockadehas showngreater therapeuticpotential.Starting from theimmunemicroenvironmentofPC，thisarticlesystematicallyreviews the biologicalcharacteristicsofPD-1andCTLA-4andthecurentstatusoftheirsingle-agentapplications，discuss theresearch advances andchalenges indual-targeted therapyforPC，and proposes the prospects forfuturedevelopment inthis field.
KeyWords：Pancreatic Neoplasms；ImmuneCheckpoint Inhibitors；Programmed CellDeath1Receptor;CTLA-4 Antigen
Research funding：National Natural Science Foundationof China（8236o51O）；LongyuanYoung Innovationand Entrepreneurship Talent（Team）Program（212088725013）；Cuiying Scientificand Technological InnovationProgramof the Second Hospital of Lanzhou University（CY2022-MS-A11）
胰腺癌（pancreaticcancer，PC）是预后最差的消化道恶性肿瘤之一，患者5年生存率不足 10%[1] 。（剩余18096字）
